ADD1 (Ab-726) Antibody

What is ADD1 (Ab-726) Antibody and what epitope does it recognize?

ADD1 (Ab-726) Antibody is a polyclonal antibody raised in rabbits that specifically recognizes the region around amino acids 724-728 (T-P-S-F-L) of the human ADD1 protein (Adducin 1 Alpha). This antibody targets the non-phosphorylated form of the peptide sequence surrounding serine 726 . The antibody has been affinity-purified using epitope-specific peptide chromatography, which enhances its specificity for the target sequence .

For phosphorylation-specific detection, researchers should note that separate antibodies exist that specifically recognize the phosphorylated serine 726 residue (pSer726) of ADD1 . Selecting the appropriate antibody depends on whether your research aims to detect total ADD1 protein or specifically its phosphorylated form.

What is the species reactivity profile of ADD1 (Ab-726) Antibody?

The ADD1 (Ab-726) Antibody demonstrates cross-reactivity with ADD1 proteins from multiple species:

What is the biological function of ADD1 and why is it relevant to study?

ADD1 (Alpha-adducin) is a membrane-cytoskeleton-associated protein that plays crucial roles in:

• Promoting the assembly of the spectrin-actin network

• Capping the fast-growing, barbed ends of actin filaments

• Recruiting spectrin to these junctions

• Binding to calmodulin for regulation

Recent research has highlighted ADD1's involvement in cardiomyocyte sarcomere disassembly during cardiac regeneration . Studies have shown that adducin expression becomes negligible at postnatal day 14 (P14), suggesting developmental regulation. Understanding ADD1 function is particularly relevant for research in:

• Cytoskeletal dynamics

• Cell morphology regulation

• Cardiac development and regeneration

• Signal transduction pathways

What are the validated applications for ADD1 (Ab-726) Antibody and their recommended dilutions?

The ADD1 (Ab-726) Antibody has been validated for multiple applications with specific recommended dilution ranges:

These dilution ranges serve as starting points for optimization in your specific experimental system . When establishing new applications or working with novel sample types, a titration experiment is strongly recommended to determine optimal antibody concentration.

How should serological testing methods be optimized when using ADD1 (Ab-726) Antibody?

When optimizing serological testing with ADD1 (Ab-726) Antibody, consider these methodological approaches:

• Titration determination: The antibody titer varies significantly depending on the assay format. For example, a precipitation assay might show a titer of 1:500, while the same antibody in ELISA might have a titer of 1:10,000 . Always indicate assay conditions when reporting titers.

• Cross-reactivity testing: Test the antibody against relevant negative controls to assess potential cross-reactions with other proteins in your experimental system .

• Antigen concentration optimization: For ELISA applications, the "sandwich" technique requires careful optimization of each layer: primary antibody → antigen → enzyme-conjugated secondary antibody. The color intensity with alkaline phosphatase (AP)/pNPP systems is generally proportional to antigen concentration but depends on multiple factors .

• Signal quantification: For precise measurements, use spectrophotometric quantification rather than visual assessment, which provides documentation and greater accuracy .

What is the recommended storage protocol to maintain antibody activity?

To preserve the activity of ADD1 (Ab-726) Antibody:

• Upon receipt: Store at -20°C or -80°C in the supplied buffer, which typically consists of phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

• Working aliquots: To minimize freeze-thaw cycles, prepare small working aliquots upon initial thawing .

• Avoid repeated freezing: The antibody documentation explicitly warns against repeated freezing and thawing, which can compromise antibody activity and specificity .

• Short-term storage: For experiments conducted over several days, antibody dilutions can be stored at 4°C, but avoid prolonged storage of diluted antibody.

• Safety note: Remember that the preservative sodium azide is toxic and should be handled with appropriate precautions .

How do I design proper controls when using ADD1 (Ab-726) Antibody in my research?

Implementing appropriate controls is crucial for interpreting results with ADD1 (Ab-726) Antibody:

• Positive controls: Include samples known to express ADD1, such as:

  • Human erythrocytes (rich in adducin)

  • Cardiac tissue from young animals (as shown in sarcomere research)

  • Cell lines with documented ADD1 expression

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at the same concentration)

  • ADD1 knockout tissues/cells where available

  • Tissues from species outside the reactivity range

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide (T-P-S-F-L) to confirm signal specificity. The immunogenic peptide should block specific binding and eliminate positive signals .

• Phosphorylation-specific controls: When studying phosphorylation states of ADD1:

  • Include samples treated with phosphatase

  • Compare with phospho-specific antibody signals (pSer726)

  • Use kinase activators/inhibitors to modify phosphorylation status

How can I validate specificity when studying ADD1 variants and isoforms?

ADD1 exists in multiple variants and can form heterodimers with other adducin family members (γ or β adducin), requiring careful experimental design for specificity:

• Variant identification: The literature indicates multiple ADD1 variants (e.g., var.1 and var.2) . When studying specific variants:

  • Use genetic constructs expressing specific variants for control samples

  • Combine antibody-based detection with PCR-based isoform analysis

  • Consider using variant-specific antibodies if available

• Adducin family member discrimination:

  • When transfecting cells with ADD1 variants in the presence/absence of ADD3 (γ-adducin), avoid antibody cross-reaction between α-adducin and γ-adducin

  • Use epitope-tagged constructs to distinguish between adducin family members

  • Consider dual immunostaining to assess co-localization patterns

• Developmental expression variations: Research shows that γ-adducin expression becomes negligible at P14 in some tissues . Age-matched controls are therefore essential when studying adducin complexes across developmental stages.

What sample preparation methods are optimal for detecting ADD1 using this antibody?

Sample preparation significantly impacts the detection of ADD1 with this antibody:

• For Western blotting:

  • Use RIPA or NP-40 based lysis buffers with protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylation states

  • For membrane-associated proteins like ADD1, ensure thorough membrane disruption

  • Consider cross-linkers for preserving protein-protein interactions within the spectrin-actin network

• For immunohistochemistry/immunofluorescence:

  • Paraformaldehyde fixation (4%) is generally effective

  • For cardiac tissue specifically, perfusion fixation may improve antigen preservation

  • Antigen retrieval methods (heat-induced or enzymatic) may be necessary

  • When studying sarcomere structure, consider specialized fixatives that preserve cytoskeletal architecture

• For co-immunoprecipitation studies:

  • Gentler lysis conditions may be required to maintain protein-protein interactions

  • Consider membrane fractionation techniques to enrich for membrane-associated ADD1

How can I resolve weak or absent signal issues when using ADD1 (Ab-726) Antibody?

When facing weak or absent signals with ADD1 (Ab-726) Antibody, systematically evaluate:

• Antibody concentration: The recommended dilution ranges (1:500-1:3000 for WB; 1:50-1:200 for IHC; 1:100-1:500 for IF) are starting points . Try a more concentrated antibody solution if signals are weak.

• Antigen accessibility:

  • For IHC/IF: Test different antigen retrieval methods (citrate buffer, EDTA buffer, enzymatic retrieval)

  • For WB: Ensure complete protein denaturation with adequate SDS and reducing agents

  • Consider native vs. denatured conditions, as epitope accessibility may differ

• Detection system sensitivity:

  • Switch to a more sensitive detection system (e.g., from chromogenic to chemiluminescent for WB)

  • Use signal amplification methods like tyramide signal amplification for IHC/IF

  • Extend primary antibody incubation time (overnight at 4°C)

• Sample-specific issues:

  • Check for protease activity in your samples

  • Verify that the developmental stage/physiological state of your samples is appropriate for ADD1 expression

  • Consider that adducin expression varies significantly across development

How should I interpret complex banding patterns in Western blots using ADD1 (Ab-726) Antibody?

ADD1 Western blot interpretation requires understanding several factors that may result in complex banding patterns:

• Expected molecular weight: Human ADD1 has a predicted molecular weight of approximately 81 kDa, but post-translational modifications and splice variants can alter migration patterns.

• Multiple bands interpretation:

  • Bands at different molecular weights may represent splice variants or isoforms (var.1, var.2)

  • Higher molecular weight bands might indicate post-translational modifications such as phosphorylation

  • Lower molecular weight bands could represent degradation products or proteolytic processing

• Phosphorylation status influences:

  • Compare with phospho-specific antibody (pSer726) results

  • Treatment with phosphatase can help identify phosphorylation-dependent band shifts

• Heterodimer vs. homodimer bands:

  • ADD1 can form homodimers with itself or heterodimers with γ or β adducin

  • Higher molecular weight bands might represent these dimeric forms

  • Use denaturing conditions that disrupt these interactions to simplify interpretation

• Validation approach: When encountering unexpected bands, validate with alternative antibodies targeting different epitopes of ADD1 and compare patterns.

How can I reliably compare ADD1 expression levels across different experimental conditions?

For reliable quantitative comparison of ADD1 expression:

• Standardized loading controls:

  • For general protein normalization, use housekeeping proteins (β-actin, GAPDH)

  • For membrane fraction analysis, consider membrane-specific loading controls (Na⁺/K⁺-ATPase)

  • For cytoskeletal studies, use alternative cytoskeletal proteins that are not expected to change in your experimental system

• Internal reference standards:

  • Include a common reference sample across all blots/gels for inter-blot normalization

  • Consider using recombinant ADD1 protein as a standard curve for absolute quantification

• Quantification methodology:

  • Use digital image analysis with linear dynamic range

  • Ensure that signal intensity falls within the linear range of detection

  • When using densitometry, subtract local background for each lane

• Statistical approach:

  • Run multiple biological replicates (minimum n=3)

  • Use appropriate statistical tests based on data distribution

  • Consider normalization methods appropriate for your experimental design

How can ADD1 (Ab-726) Antibody be used to study the role of adducin in sarcomere dynamics?

Recent research has identified ADD1 as a regulator of sarcomere disassembly in cardiomyocytes, offering new applications for this antibody:

• Developmental studies: The antibody can be used to track ADD1 expression changes during cardiac development, where γ-adducin expression becomes negligible at P14, potentially explaining age-dependent loss of sarcomere disassembly capability .

• Regeneration models: In myocardial infarction models, ADD1 has been identified as differentially associated with Troponin T (Tnnt2) during regenerative windows (P1MI) compared to non-regenerative conditions (P7MI) . This antibody can be used to:

  • Track ADD1 redistribution during regeneration

  • Assess co-localization with sarcomeric proteins

  • Evaluate changes in phosphorylation status during regenerative processes

• Transgenic model analysis: When studying transgenic models with cardiac-specific expression of ADD1:

  • Use the antibody to confirm transgene expression levels

  • Assess subcellular localization of overexpressed ADD1

  • Differentiate between endogenous and transgenic ADD1 when using tagged constructs

• Co-immunoprecipitation studies: The antibody can be used to pull down ADD1 complexes to identify interaction partners in the sarcomere during different developmental or disease states.

What methodological approaches can be used to study ADD1 phosphorylation states in signaling pathways?

To investigate ADD1 phosphorylation in signaling contexts:

• Comparative antibody approach: Use both the non-phospho ADD1 (Ab-726) Antibody and phospho-specific antibodies (pSer726) to:

  • Determine the ratio of phosphorylated to total ADD1

  • Track dynamic changes in phosphorylation following stimuli

  • Map phosphorylation changes in different subcellular compartments

• Pharmacological interventions:

  • Use kinase inhibitors specific to pathways known to regulate ADD1 (PKC, Rho-kinase)

  • Apply phosphatase inhibitors to preserve phosphorylation states

  • Design time-course experiments to track phosphorylation dynamics following stimulus application

• Genetic manipulation strategies:

  • Generate phospho-mimetic (S726D/E) and phospho-dead (S726A) mutants

  • Compare cellular localization and function of these mutants using the antibody

  • Assess how these mutations affect interaction with binding partners

• Mass spectrometry integration:

  • Use immunoprecipitation with ADD1 (Ab-726) Antibody followed by mass spectrometry

  • Identify multiple phosphorylation sites beyond Ser726

  • Quantify phosphorylation stoichiometry at different sites

How can ADD1 (Ab-726) Antibody be applied in studies of cytoskeletal remodeling in pathological conditions?

For investigating cytoskeletal remodeling in disease states:

• Subcellular redistribution analysis:

  • Track changes in ADD1 localization using immunofluorescence with ADD1 (Ab-726) Antibody

  • Perform co-localization studies with markers of membrane domains, cytoskeletal structures, and junctional complexes

  • Quantify changes in membrane vs. cytoplasmic distribution using subcellular fractionation followed by Western blotting

• Disease model applications:

  • In hypertension models: Examine ADD1 phosphorylation and localization changes in vascular smooth muscle cells

  • In cardiac pathologies: Study ADD1's role in sarcomere remodeling after injury

  • In renal disease: Investigate ADD1's contribution to podocyte cytoskeletal dynamics

• Multi-dimensional analysis:

  • Combine ADD1 immunostaining with functional assays of cellular mechanics

  • Correlate ADD1 expression/localization with measurements of membrane rigidity

  • Use live-cell imaging techniques with tagged ADD1 constructs and validate with antibody staining in fixed cells

• Therapeutic intervention assessment:

  • Use the antibody to evaluate how cytoskeleton-targeting compounds affect ADD1 expression and localization

  • Assess whether therapeutic interventions normalize pathological changes in ADD1 distribution or phosphorylation

What are the key limitations of the ADD1 (Ab-726) Antibody and how can researchers address them?

Understanding the antibody's limitations enables better experimental design:

• Epitope accessibility concerns:

  • The antibody targets a specific sequence (T-P-S-F-L) that may be masked in certain protein conformations or complexes

  • Solution: Try multiple fixation/extraction methods to optimize epitope exposure

• Cross-reactivity potential:

  • While purified by affinity chromatography, polyclonal antibodies may retain some cross-reactivity

  • Solution: Always include appropriate negative controls and validate in your specific system

• Phosphorylation interference:

  • The antibody targets a region containing a phosphorylation site (Ser726), which might affect binding if phosphorylated

  • Solution: Use paired experiments with phospho-specific antibodies for comprehensive analysis

• Batch-to-batch variability:

  • Polyclonal antibodies inherently show some batch variation

  • Solution: Record lot numbers and consider purchasing sufficient quantity from a single lot for long-term projects

What emerging applications and technologies could enhance ADD1 research beyond traditional antibody-based methods?

Future research on ADD1 may benefit from complementary approaches:

• CRISPR-based tagging:

  • Endogenous tagging of ADD1 to avoid overexpression artifacts

  • Development of split-protein complementation assays to study ADD1 interactions

  • Creation of conditional knockouts for tissue-specific functional studies

• Advanced imaging methods:

  • Super-resolution microscopy to study the nanoscale organization of ADD1 within the membrane-cytoskeleton interface

  • Live-cell imaging combined with optogenetic control of ADD1 function

  • Correlative light and electron microscopy to connect ADD1 localization with ultrastructural features

• Proteomics approaches:

  • Proximity labeling methods (BioID, APEX) to identify the ADD1 interaction network

  • Crosslinking mass spectrometry to map structural details of ADD1 complexes

  • Thermal proteome profiling to study ADD1 stability and interactions under various conditions

• Systems biology integration:

  • Multi-omics approaches connecting ADD1 function to broader cellular programs

  • Computational modeling of cytoskeletal dynamics incorporating ADD1 regulatory mechanisms

  • Network analysis of ADD1's role in development and disease states